Privi Speciality Chemicals Ltd
PRIVISCLPrivi Speciality Chemicals Ltd's earnings have outrun its stock. EPS grew +75.1% in a year against a +52.1% price move.
The sharpest disagreement: Promoters moved −13.4 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a confirmed uptrend (73 weeks in) while the P/E sits at the 48th percentile of its own 9-year range. Underneath, the last four quarters read improving — profit +43.1% year on year, and 198% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Privi Speciality Chemicals Ltd trades at ₹3,556, in a confirmed uptrend and 73 weeks into that stage. That is +11.2% against its own 200-day average. It sits at 86% of a 52-week range of ₹2,670 to ₹3,695. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 73 of stage 2, confirmed. At ₹3,556 it trades +11.2% versus its 200-day average and sits at 86% of its 52-week range (₹2,670–₹3,695).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +1,539% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-08-14) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Privi Speciality Chemicals Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: MID_CYCLE. Still open: A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.
Our read, 22 August 2026. India's leading aroma chemicals manufacturer expanding capacity from 48,000 MT to 54,000 MT and transitioning into high-margin specialty molecules amidst structural China-plus-one tailwinds, offset by execution friction from repeated capex commissioning delays.
From the numbers. PE of 43.0 is at the 51st percentile of its 10-year band (median 42.7), reflecting multiple compression of 76.5% from the Sep 2023 peak of 182.8. Trailing EPS expanded from ₹24.27 in FY24 to ₹83.77 in FY26 and ₹89.47…
From the price. Price stage 2, week 73 — above its 200-day line, relative strength falling.
From the research. India's leading aroma chemicals manufacturer expanding capacity from 48,000 MT to 54,000 MT and transitioning into high-margin specialty molecules amidst structural China-plus-one tailwinds, offset by execution friction…
🚨 Where they disagree. PE of 43.0 is at the 51st percentile of its 10-year band (median 42.7), reflecting multiple compression of 76.5% from the Sep 2023 peak of 182.8. Trailing EPS expanded from ₹24.27 in FY24 to ₹83.77 in FY26 and ₹89.47 TTM. The deterministic normalized verdict flags PEAK_MARGIN_VALUE_TRAP as trailing OPM (23-27%) sits at the 85th percentile versus normalized OPM of 16.6% (where normalized PE rises to 72.8x, 91st percentile). However, CST backward integration, ~90% capacity utilization, and 70% annual contracts provide near-term margin defensibility as guided by management. DII holding rose from 3.75% in March 2023 to 10.25% in December 2025, confirming institutional accumulation.
What is proven. India's leading aroma chemicals manufacturer expanding capacity from 48,000 MT to 54,000 MT and transitioning into high-margin specialty molecules amidst structural China-plus-one tailwinds, offset by execution friction from repeated capex commissioning delays.
What is not proven yet. A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.
🚨 What would change our mind. A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.
Layer 1 read, 22 August 2026 — KEEP. Profits tripled in two years at a mid-range rating — but the new plant has slipped four times. Privi makes fragrance ingredients for every one of the top-15 global blenders and has grown profit year on year in each of the last four quarters, by 100%, 71%, 47% and 43%, with interest cost falling every single quarter from 24 crore to 17 crore and an 18% tariff advantage over Chinese rivals into Western markets. The share trades at 38.9 times earnings, roughly the middle of its own ten-year range, so the market has not yet paid up for this. Two things hold it back: the capacity expansion to 54,000 tonnes has been re-promised four times and now points at September 2026, and the operating margin has slipped from 27% to 23% over three quarters while management guides only to "20% plus"…
What would change Layer 1’s mind. The September 2026 quarter passing with Phase 1 still not commissioned — a fifth deferral. Four slips can be read as construction friction; a fifth, against a company whose entire forward case is 6,000 tonnes of new capacity and a stated path to 5,000 crore of revenue, means the capacity story is not real and the rating has nothing behind it. A second, independent flip: operating margin printing below 20% for two consecutive quarters, which would confirm the roll from 27% is mean reversion…
Layer 2 read, 22 August 2026 — ADVANCE. Broad volume recovery supports one more step, but Privi must finally commission Phase 1 in September. Privi's Q1 revenue rose 19.1% and profit rose 43.1%, with lower interest helping rather than a higher margin [C005/C009]. The external sector timeline says the recovery has become broad [sector_timeline:C3/C4/Q12], but it also records a HEADWIND from feedstock and shipping costs and names Privi's fourth commissioning delay.
What would change Layer 2’s mind. Flip to DROP if Phase 1 is not commercially producing by the Q3 FY27 boundary, or if EBITDA margin stays below 20% for two consecutive quarters because pass-through fails. Upgrade only after commissioning and volume appear together.
Layer 3 read, 22 August 2026 — BENCH. The recovery is real, but repeated plant delays make this a wait, not a buy. The latest call confirms that Phase 1 moved from the promised June completion to September, so Timeline risk R1 is aligned and remains unresolved. Commodity inflation also cut gross margin despite partial contract protection, while the promoter stake reduction adds a separate governance concern.
What would change Layer 3’s mind. Confirmed commercial production from Phase 1 by September 2026, with no further promoter reduction and operating margin staying above 20%, would flip BENCH to DEPLOY.
The test written in advance. A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure. — the thesis as written as stated by the next result.
The test written in advance. Phase 1 Capex Fourth Completion Delay — Phase 1 Capex Fourth Completion Delay Confirmation of mechanical completion and commercial production start in Q2 FY27 concall. by the next result.
The test written in advance. Raw Material (Alpha-Pinene / GTO) Price Volatility — Raw Material (Alpha-Pinene / GTO) Price Volatility Raw material cost percentage of sales remaining within guided 52.0-54.0% range. by the next result.
What the company does. Trailing 12-month EPS reached ₹89.47 with FY26 PAT up 75.2% YoY and operating margin sustaining at 23-27% across the past five quarters. Valuation multiple compressed 76.5% from peak to 43.0x PE (51st percentile of 10-year history), representing earnings-driven multiple normalization against a 42.7x median. Phase 1 capex adding 6,000 MT is rescheduled to September 2026 following four consecutive delays, making commercialization verification the primary near-term operational milestone.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Operating Leverage and Continuous… | HIGH | — | Fixed-cost absorption across ~90% capacity utilization and continuous processing drove FY26 EBITDA up 42.1% YoY with quarterly… | A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw… |
| China-Plus-One Export Market Share Gains | HIGH | — | An 18% tariff advantage over Chinese manufacturers and EcoVadis Platinum ESG certification position Privi to capture export… | A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw… |
| Phase 1 Capacity Expansion to 54,000 MT | HIGH | — | Phase 1 capex adds 6,000 MT (+12.5%) taking total capacity from 48,000 MT to 54,000 MT, scheduled for September 2026 completion… | A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw… |
| High-Margin Specialty Molecules and… | MEDIUM | — | New specialty chemistry platforms (Furfural-to-Maltol, Cyclafentanol) target ₹1,000 Cr+ revenue at 27-28% margins with… | A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw… |
Lever 1 · Operating leverage — BUILDING. Fixed-cost absorption across ~90% capacity utilization and continuous processing drove FY26 EBITDA up 42.1% YoY with quarterly interest costs falling to ₹17 Cr. What proves it keeps working: Operating Leverage and Continuous Distillation Efficiency. It stops working if A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.
Lever 2 · Value-added mix — BUILDING. An 18% tariff advantage over Chinese manufacturers and EcoVadis Platinum ESG certification position Privi to capture export demand across global blenders. What proves it keeps working: China-Plus-One Export Market Share Gains. It stops working if A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.
Lever 3 · Management change — BUILDING. Phase 1 capex adds 6,000 MT (+12.5%) taking total capacity from 48,000 MT to 54,000 MT, scheduled for September 2026 completion to unlock FY27 volume ramp. What proves it keeps working: Phase 1 Capacity Expansion to 54,000 MT. It stops working if A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.
Lever 4 · Paying down debt — BUILDING. New specialty chemistry platforms (Furfural-to-Maltol, Cyclafentanol) target ₹1,000 Cr+ revenue at 27-28% margins with mechanical completion around mid-FY28. What proves it keeps working: High-Margin Specialty Molecules and Biomass Platform. It stops working if A delay of Phase 1 capex commissioning beyond Q3 FY27 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.
Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Privi Speciality Chemicals Ltd reported ₹666 Cr of revenue in the Jun 26 quarter, +19.1% year on year. That is the 10th straight quarter of year-on-year growth. Over 9 years it has compounded at 17.6% a year. The last full year, FY26, came in at ₹2,564 Cr. The last four reported quarters add to ₹2,672 Cr.
FY26 revenue came in at ₹2,564 Cr (+22.0% on the year), capping 9 years at 17.6% compound. The latest quarter (Jun 26) printed ₹666 Cr, +19.1% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +21.8% growth against the decade's 17.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +21.6% over the last 4 quarters against +21.6%/yr over the last 8 — stabilising; TTM profit +62.1% vs +67.4%/yr — rolling over.
FY26-Q4. revenue ₹722 Cr and profit ₹94 Cr as reported.
FY27-Q1. revenue ₹666 Cr and profit ₹83 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Privi Speciality Chemicals Ltd's operating margin is 23.0% in the Jun 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged 12.0% to 25.0%. The current quarter sits inside that band.
Why this happened. Privi's operating leverage mechanism is demonstrated by FY26 results where 21.7% revenue growth translated into 42.1% operating profit growth and 75.2% PAT growth. High asset utilization (~90%) across core aroma chemical distillation columns combined with engineering optimizations (steam conservation, yield maximization) maintained operating margins between 23% and 27% across the past four quarters. Concurrently, quarterly interest expense declined from ₹24 Cr in Jun 2025 to ₹17 Cr in Jun 2026, delivering financial leverage.
The latest quarter's operating margin is 23.0%, −1.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 12.0%–25.0%, and FY26's 25.0% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −0.8 pp year on year while gross margin went −6.5 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
FY26-Q4. revenue ₹722 Cr and profit ₹94 Cr as reported.
FY27-Q1. revenue ₹666 Cr and profit ₹83 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Privi Speciality Chemicals Ltd earned ₹83.0 Cr of net profit in the Jun 26 quarter, +43.1% year on year. It is the 9th consecutive quarter of growth. Full-year FY26 profit was ₹317 Cr. The 9-year compound rate is 31.5%. That is 12.5% of the quarter's revenue. The same quarter a year earlier earned ₹58.0 Cr.
Jun 26 profit was ₹83.0 Cr, +43.1% year on year — the 9th consecutive quarter of growth. On the full year, FY26 printed ₹317 Cr (+71.4%), and the 9-year compound rate is 31.5%.
Why profit moved: revenue contributed +19.1% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +65.1% vs revenue +21.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
FY26-Q4. revenue ₹722 Cr and profit ₹94 Cr as reported.
FY27-Q1. revenue ₹666 Cr and profit ₹83 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 198% of Privi Speciality Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹550 Cr of operating cash against ₹317 Cr of profit. After ₹330 Cr of capital spending, ₹220 Cr was left as free cash.
FY26: operating cash of ₹550 Cr against reported profit of ₹317 Cr, leaving free cash of ₹220 Cr after ₹330 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 198% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 198%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Privi Speciality Chemicals Ltd's cash conversion cycle runs 160 days in FY26, up from 155 days in FY21. Capital spending ran ₹765 Cr over the last 3 years. At FY26 sales of ₹2,564 Cr each day of that cycle holds about ₹7.0 Cr, so roughly ₹1,124 Cr sits inside the business at any moment.
FY26: debtors at 75 days, inventory at 235 days — roughly 7.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 160 days, looser than FY21's 155.
The full loop: cash goes out to suppliers and production on day 0; stock waits 235 days to sell; customers pay about 75 days after that; and suppliers themselves are paid at 150 days — netting out to the 160-day cycle.
In money terms: at FY26 sales of ₹2,564 Cr, each day of the cycle holds about ₹7.0 Cr — so the 160-day loop keeps roughly ₹1,124 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹765 Cr over the last 3 fiscal years against ₹399 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹314 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Privi Speciality Chemicals Ltd earns a ROCE of 22% in FY26. That is up from a trough of 6% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 12.4% net margin on 0.81× asset turns.
FY26 ROCE is 22%, recovered from a FY23 trough of 6% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 12.4% net margin × 0.81× asset turns × 2.25× balance-sheet leverage ≈ 22.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.9% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Privi Speciality Chemicals Ltd carries ₹1,021 Cr of borrowings against ₹1,412 Cr of equity in FY26, a debt-to-equity of 0.72. Operating profit covers the interest bill 8×. Over 5 years borrowings went from ₹537 Cr to ₹1,021 Cr. Capital spending ran ₹765 Cr across the last 3 of those years.
Why this happened. Privi is expanding beyond core Pinene aroma chemicals into specialized high-value verticals. The Furfural-to-Maltol platform converts renewable corn cob waste into flavor and pharma-grade molecules, targeting 25% global market share in a segment where >95% production is currently concentrated in China. Mechanical completion is slated for mid-next financial year with H2 commercial contributions, targeting ₹1,000 Cr+ revenue at standalone margins of 27-28%.
FY26: borrowings of ₹1,021 Cr against equity of ₹1,412 Cr — a debt-to-equity of 0.72. Operating profit covers the interest bill 8×. Over 5 years borrowings went from ₹537 Cr to ₹1,021 Cr while capital spending ran ₹765 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.9% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 13.4 points of Privi Speciality Chemicals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 60.6% of the company. Domestic institutions moved +7.2 points over the same window, to 10.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
Why this happened. The Phase 1 brownfield expansion increases existing-product capacity by 6,000 MT to 54,000 MT per annum. Although commissioning has been delayed across consecutive calls (December 2025 to April 2026, June 2026, and now September 2026), mechanical completion in Q2 FY27 will enable commercial volume ramp in H2 FY27, supporting management's standalone 20% FY27 revenue growth guidance.
The register over the last two years — Promoters: −13.4 points over 8 quarters to 60.6%; Domestic institutions: +7.2 points over 8 quarters to 10.1%; Foreign institutions: +1.5 points over 8 quarters to 1.9%.
🚨 Why the register moved: promoters drove it (−13.4 points), absorbed on the other side by domestic institutions (+7.2 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Privi Speciality Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Privi Speciality Chemicals Ltd trades at 39.7× P/E, mid-range by its own standards (48th percentile). Its long-run median P/E is 40.8×, measured across 9.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 39.7× is mid-range by its own standards (48th percentile), against a long-run median of 40.8× measured over 9.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +75.1% against a +52.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +14.7%/yr price move, ~+26.5%/yr came from earnings growth and ~−11.8 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.9% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 26 August 2026 price, Privi Speciality Chemicals Ltd was paying for profit growth of about 21.9% a year. Profit itself has compounded 31.5% a year over the past 9 years. Today the market pays 39.7× P/E, the 48th percentile of its own 9-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 26 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Privi Speciality Chemicals Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +426.9% at its peak to +62.1% but is still expanding, ROCE lifting at 22.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +22.0% | +16.8% | +15.0% | — |
| Profit | +71.4% | +147.1% | +22.1% | — |
| EPS | +75.1% | +145.2% | +22.9% | — |
| Share price | +52.1% | +42.8% | +14.7% | +27.4% |
4-Factor Sector Score
59.9/100 — rank 6 of 28 in Speciality Chemicals · 75% evidence confidence
Privi Speciality Chemicals Ltd scores 59.9 out of 100 against the 28 companies it is compared with in Speciality Chemicals, ranking 6. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 25 + 17.9 + 9.5 + 7.5 = 59.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Privi Speciality Chemicals Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Phase One Capex Completion Delayed · 31 July 2026. Management previously committed to completing phase one by June 30, 2026, after earlier targeting commercialization by March or April 2026. The latest call moved completion to September 2026 without explaining the cause of the delay, which is material for capacity and revenue assumptions.
Specialty Product Commercialization Timeline Shifted · 31 July 2026. In February 2026, management targeted mechanical completion of the specialty product projects by June of the next financial year, with commercial production expected shortly after trials. In the latest call, management moved mechanical completion to around the middle of next year and deferred contributions to the second half of the next financial year, without explaining the schedule change.
JV Counterparty and Exclusive Customer Changed · 31 July 2026. In May 2026, management identified the JV as a Givaudan partnership and stated that its products would be manufactured exclusively for Givaudan. In the latest call, management referred to the same additional INR50 crore equity expansion but said the JV output would be sold exclusively to Teijin, without clarifying whether the partner changed or a separate JV is being discussed.
Three-Year Capex Plan Reduced or Recast · 31 July 2026. The February 2026 call outlined approximately INR1,200 crores of investment over three years across phases one, two, and three. The latest call cited only INR850-900 crores for this year and the following two years, a potential 25%-29% reduction in the stated investment plan, with no explanation of whether this is a reduced program or only the remaining capex requirement.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Panama Petrochem LtdPANAMAPET | 74.9/100Favorable setup100% evidence | LEADER | 28.1/35 Revenue 45.9% · PAT 100% · OPM change 14 pp 100% evidence | 14.9/25 ROCE 19.2% · OPM 22% 100% evidence | 15.4/20 P/E 6.1× · PEG 0.55 100% evidence | 16.5/20 RS sector 18.7% · RS bench 46.9% · 1Y 64.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.1 + 14.9 + 15.4 + 16.5 = 74.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sunshield Chemicals Ltd530845 | 69.8/100Favorable setup76% evidence | FADING | 28.0/35 Revenue 12.9% · PAT 100% · OPM change 5 pp 95% evidence | 16.6/25 ROCE 19.9% · OPM 16% 76% evidence | 11.3/20 P/E 29.1× · PEG — 50% evidence | 13.9/20 RS sector 2.3% · RS bench 24.5% · 1Y 16.2%10 of 11 weeks ahead 70% evidence |
| Exact sum: 28 + 16.6 + 11.3 + 13.9 = 69.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Vikram Thermo (India) Ltd530477 | 65.5/100Favorable setup67% evidence | BREAKING OUT | 25.5/35 Revenue 16.9% · PAT 41.9% · OPM change 8 pp 95% evidence | 19.8/25 ROCE 36.2% · OPM 48% 76% evidence | 7.9/20 P/E 24.3× · PEG — 50% evidence | 12.3/20 RS sector — · RS bench 83.6% · 1Y —10 of 10 weeks ahead 25% evidence |
| Exact sum: 25.5 + 19.8 + 7.9 + 12.3 = 65.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 4Black Rose Industries LtdBLACKROSE | 64.2/100Mixed-positive evidence72% evidence | BREAKING OUT | 22.0/35 Revenue 8.6% · PAT 28.6% · OPM change 6 pp 95% evidence | 17.1/25 ROCE 18.7% · OPM 16% 95% evidence | 14.5/20 P/E 19.2× · PEG — 50% evidence | 10.6/20 RS sector — · RS bench 11.6% · 1Y —4 of 6 weeks ahead 25% evidence |
| Exact sum: 22 + 17.1 + 14.5 + 10.6 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Yasho Industries LtdYASHO | 62.9/100Mixed-positive evidence87% evidence | BREAKING OUT | 29.3/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence | 8.6/25 ROCE 8.9% · OPM 24% 100% evidence | 12.0/20 P/E 87.6× · PEG 1.15 65% evidence | 13.0/20 RS sector -2.4% · RS bench 102% · 1Y 131.1%11 of 11 weeks ahead 70% evidence |
| Exact sum: 29.3 + 8.6 + 12 + 13 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Privi Speciality Chemicals Ltdthis pagePRIVISCL | 59.9/100Mixed-positive evidence75% evidence | FADING | 25.0/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence | 17.9/25 ROCE 22.3% · OPM 23% 76% evidence | 9.5/20 P/E 39.7× · PEG — 15% evidence | 7.5/20 RS sector -8.1% · RS bench 15.3% · 1Y 55.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 17.9 + 9.5 + 7.5 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aether Industries LtdAETHER | 58.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 24.4/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence | 10.7/25 ROCE 11.9% · OPM 31% 100% evidence | 4.2/20 P/E 92.6× · PEG 8.9 100% evidence | 19.1/20 RS sector 23.6% · RS bench 53.6% · 1Y 125.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.7 + 4.2 + 19.1 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8DMCC Speciality Chemicals LtdDMCC | 56.8/100Mixed-positive evidence80% evidence | TURNING | 24.4/35 Revenue 49.7% · PAT 42.9% · OPM change 0 pp 95% evidence | 11.0/25 ROCE 14.8% · OPM 13% 95% evidence | 11.4/20 P/E 17.9× · PEG — 15% evidence | 10.0/20 RS sector -12.3% · RS bench 10% · 1Y -6.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 11 + 11.4 + 10 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Pidilite Industries LtdPIDILITIND | 56.7/100Mixed-positive evidence100% evidence | FADING | 22.6/35 Revenue 14.1% · PAT 21.5% · OPM change 1 pp 100% evidence | 20.6/25 ROCE 31% · OPM 26% 100% evidence | 7.9/20 P/E 60.2× · PEG 3.8 100% evidence | 5.6/20 RS sector -15.4% · RS bench 6.4% · 1Y 1.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 20.6 + 7.9 + 5.6 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Tatva Chintan Pharma Chem LtdTATVA | 56.0/100Mixed-positive evidence93% evidence | BREAKING OUT | 30.4/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence | 6.5/25 ROCE 7.2% · OPM 19% 100% evidence | 4.7/20 P/E 71.8× · PEG 5.63 65% evidence | 14.4/20 RS sector -1.5% · RS bench 23.3% · 1Y 61.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.4 + 6.5 + 4.7 + 14.4 = 56 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Fineotex Chemical LtdFCL | 54.0/100Mixed-positive evidence100% evidence | LEADER | 18.4/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence | 12.7/25 ROCE 18.3% · OPM 16% 100% evidence | 3.0/20 P/E 54.9× · PEG 4.19 100% evidence | 19.9/20 RS sector 58% · RS bench 94.1% · 1Y 143.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 12.7 + 3 + 19.9 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Aarti Industries LtdAARTIIND | 53.5/100Mixed-positive evidence100% evidence | BREAKING OUT | 27.7/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence | 8.3/25 ROCE 6.9% · OPM 16% 100% evidence | 9.0/20 P/E 34.2× · PEG 2.05 100% evidence | 8.5/20 RS sector -8.2% · RS bench 15.1% · 1Y 30.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 27.7 + 8.3 + 9 + 8.5 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Kronox Lab Sciences LtdKRONOX | 53.3/100Mixed-positive evidence65% evidence | BREAKING OUT | 9.4/35 Revenue 6.1% · PAT 11.6% · OPM change -1.1 pp 95% evidence | 21.6/25 ROCE 36% · OPM 31.7% 95% evidence | 10.8/20 P/E 22.8× · PEG — 15% evidence | 11.5/20 RS sector — · RS bench 24.8% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 9.4 + 21.6 + 10.8 + 11.5 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Chemcon Speciality Chemicals LtdCHEMCON | 51.1/100Mixed-positive evidence81% evidence | TURNING | 21.0/35 Revenue 16.7% · PAT 12% · OPM change 8 pp 95% evidence | 10.7/25 ROCE 6.3% · OPM 23% 95% evidence | 12.1/20 P/E 28.2× · PEG — 50% evidence | 7.3/20 RS sector -21.7% · RS bench 13.7% · 1Y 4.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 10.7 + 12.1 + 7.3 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Vishnu Chemicals LtdVISHNU | 47.7/100Mixed-negative evidence100% evidence | BREAKING OUT | 15.5/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence | 11.3/25 ROCE 16.4% · OPM 15% 100% evidence | 5.6/20 P/E 32.1× · PEG 2.82 100% evidence | 15.3/20 RS sector 4.7% · RS bench 31.2% · 1Y 48.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.3 + 5.6 + 15.3 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 31.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Galaxy Surfactants LtdGALAXYSURF | 47.3/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.5/35 Revenue 27% · PAT 15.7% · OPM change 4 pp 100% evidence | 9.4/25 ROCE 13.5% · OPM 14% 100% evidence | 9.6/20 P/E 21.3× · PEG 4.39 100% evidence | 8.8/20 RS sector -12.1% · RS bench 11.3% · 1Y -6.7%8 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 9.4 + 9.6 + 8.8 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Alkyl Amines Chemicals LtdALKYLAMINE | 46.8/100Mixed-negative evidence100% evidence | FADING | 18.4/35 Revenue 5.1% · PAT 21% · OPM change 6 pp 100% evidence | 15.6/25 ROCE 16.6% · OPM 25% 100% evidence | 5.6/20 P/E 42.4× · PEG 5.37 100% evidence | 7.2/20 RS sector -10.8% · RS bench 11.6% · 1Y -9.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 15.6 + 5.6 + 7.2 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Vinati Organics LtdVINATIORGA | 44.4/100Mixed-negative evidence82% evidence | TURNING | 11.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence | 17.5/25 ROCE 19.8% · OPM 24% 76% evidence | 13.4/20 P/E 29.9× · PEG — 50% evidence | 2.3/20 RS sector -28.7% · RS bench -9.8% · 1Y -23.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 17.5 + 13.4 + 2.3 = 44.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Amal LtdAMAL | 43.0/100Mixed-negative evidence69% evidence | 8.0/35 Revenue 79% · PAT -23.1% · OPM change -7 pp 95% evidence | 16.4/25 ROCE 26% · OPM 18% 76% evidence | 10.0/20 P/E 30.7× · PEG — 15% evidence | 8.6/20 RS sector -18.2% · RS bench 15.4% · 1Y -20%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 8 + 16.4 + 10 + 8.6 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Platinum Industries LtdPLATIND | 42.5/100Mixed-negative evidence74% evidence | BASING | 12.8/35 Revenue 9.6% · PAT 6.5% · OPM change -1 pp 95% evidence | 12.3/25 ROCE 15.7% · OPM 12% 95% evidence | 10.6/20 P/E 23.9× · PEG — 15% evidence | 6.8/20 RS sector -10.6% · RS bench -6.1% · 1Y -22.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.3 + 10.6 + 6.8 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Grauer & Weil (India) LtdGRAUWEIL | 41.5/100Mixed-negative evidence100% evidence | TURNING | 10.4/35 Revenue 10.1% · PAT 6.6% · OPM change -5 pp 100% evidence | 16.1/25 ROCE 20.6% · OPM 16% 100% evidence | 8.2/20 P/E 21.4× · PEG 4.01 100% evidence | 6.8/20 RS sector -17.8% · RS bench 3.4% · 1Y -18.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 16.1 + 8.2 + 6.8 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Anupam Rasayan India LtdANURAS | 41.5/100Mixed-negative evidence82% evidence | ASLEEP | 20.0/35 Revenue 51.7% · PAT 14.8% · OPM change -1 pp 95% evidence | 10.5/25 ROCE 7.4% · OPM 25% 76% evidence | 8.3/20 P/E 79.5× · PEG — 50% evidence | 2.7/20 RS sector -21.7% · RS bench -1% · 1Y 9.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 10.5 + 8.3 + 2.7 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Neogen Chemicals LtdNEOGEN | 40.5/100Mixed-negative evidence90% evidence | LEADER | 14.7/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence | 6.7/25 ROCE 6.5% · OPM 19% 100% evidence | 5.2/20 P/E 183× · PEG — 50% evidence | 13.9/20 RS sector 22.9% · RS bench 52% · 1Y 59.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 6.7 + 5.2 + 13.9 = 40.5 · Decision use: Price leads the evidence: RS versus the benchmark is 52%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 24Paushak LtdPAUSHAKLTD | 37.0/100Mixed-negative evidence81% evidence | BREAKING OUT | 11.9/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence | 10.0/25 ROCE 8.3% · OPM 31% 95% evidence | 7.5/20 P/E 42.4× · PEG — 50% evidence | 7.6/20 RS sector -27.5% · RS bench 28% · 1Y -4.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 10 + 7.5 + 7.6 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Clean Science & Technology LtdCLEAN | 36.3/100Mixed-negative evidence94% evidence | BREAKING OUT | 4.5/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence | 18.5/25 ROCE 20.7% · OPM 36% 100% evidence | 7.8/20 P/E 38.4× · PEG 6.24 100% evidence | 5.5/20 RS sector -24.4% · RS bench 1.4% · 1Y -29.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 4.5 + 18.5 + 7.8 + 5.5 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Amines & Plasticizers LtdAMNPLST | 35.5/100Mixed-negative evidence81% evidence | ASLEEP | 7.8/35 Revenue -12.4% · PAT -3% · OPM change 0.7 pp 95% evidence | 14.0/25 ROCE 16.7% · OPM 9.9% 95% evidence | 8.8/20 P/E 23.6× · PEG — 50% evidence | 4.9/20 RS sector -19.4% · RS bench -9.2% · 1Y -27.6%5 of 10 weeks ahead 70% evidence |
| Exact sum: 7.8 + 14 + 8.8 + 4.9 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Transpek Industry LtdTRANSPEK | 34.5/100Adverse evidence81% evidence | TURNING | 6.4/35 Revenue -5.2% · PAT -29.1% · OPM change -2.3 pp 95% evidence | 9.1/25 ROCE 8.4% · OPM 13.3% 95% evidence | 11.3/20 P/E 19.3× · PEG — 50% evidence | 7.7/20 RS sector -19.7% · RS bench 11.7% · 1Y -4.7%4 of 10 weeks ahead 70% evidence |
| Exact sum: 6.4 + 9.1 + 11.3 + 7.7 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Thirumalai Chemicals LtdTIRUMALCHM | 25.9/100Adverse evidence69% evidence | BASING | 13.1/35 Revenue -5.8% · PAT -36.9% · OPM change 12 pp 71% evidence | 1.1/25 ROCE -3.1% · OPM 6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.7/20 RS sector -39.8% · RS bench -23.6% · 1Y -49%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.1 + 1.1 + 10 + 1.7 = 25.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Privi Speciality Chemicals Ltd's share price today?
Privi Speciality Chemicals Ltd trades at ₹3,556, +52.1% over the past year. The company is valued at ₹13,891 Cr. The stock sits at 86% of its 52-week range of ₹2,670–₹3,695, +11.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 73 weeks in. — as of 11 September 2026.
What were Privi Speciality Chemicals Ltd's latest quarterly results?
Privi Speciality Chemicals Ltd reported revenue of ₹666 Cr and net profit of ₹83.0 Cr for the Jun 26 quarter. Revenue rose 19.1% and profit rose 43.1% year on year. Earnings per share were ₹21.54. The operating margin was 23.0%, 1.0 pp lower than a year earlier. — as of 11 September 2026.
What is Privi Speciality Chemicals Ltd's revenue?
Privi Speciality Chemicals Ltd reported revenue of ₹666 Cr in the Jun 26 quarter, +19.1% year on year. For the full FY26 fiscal year, revenue was ₹2,564 Cr (+22.0%). Over the last 9 years revenue compounded at 17.6% a year. — as of 11 September 2026.
What is Privi Speciality Chemicals Ltd's profit?
Privi Speciality Chemicals Ltd earned ₹83.0 Cr of net profit in the Jun 26 quarter, +43.1% year on year — the 9th straight quarter of growth. Full-year FY26 profit was ₹317 Cr. The operating margin ran 23.0% in the latest quarter. — as of 11 September 2026.
What is Privi Speciality Chemicals Ltd's market cap?
Privi Speciality Chemicals Ltd's market capitalisation is ₹13,891 Cr at a share price of ₹3,556. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Privi Speciality Chemicals Ltd's P/E ratio?
Privi Speciality Chemicals Ltd trades at a P/E of 39.7×, at the 48th percentile of its own 9-year range, against a long-run median of 40.8×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Privi Speciality Chemicals Ltd pay a dividend?
Yes — Privi Speciality Chemicals Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 9 of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Privi Speciality Chemicals Ltd overvalued?
On its own history, Privi Speciality Chemicals Ltd looks mid-range: its P/E of 39.7× sits at the 48th percentile of its 9-year range (long-run median 40.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 11 September 2026.
Is Privi Speciality Chemicals Ltd growing?
Yes — Privi Speciality Chemicals Ltd is growing: latest-quarter revenue +19.1% year on year, profit +43.1%, and the margin −1.0 pp at 23.0%. The 9-year compound rates are 17.6% (revenue) and 31.5% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Privi Speciality Chemicals Ltd performing?
Privi Speciality Chemicals Ltd is in a confirmed uptrend, 73 weeks in. Its latest quarter's revenue rose 19.1% and profit rose 43.1% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Privi Speciality Chemicals Ltd in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +426.9% at its peak to +62.1% but is still expanding, ROCE lifting at 22.0%. The read comes from the last 12 quarters of growth (revenue growth +21.6% latest, profit growth +62.1% latest, eps growth +60.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Privi Speciality Chemicals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 73 of stage 2), trading +11.2% versus its 200-day average and at 86% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Privi Speciality Chemicals Ltd beating the market?
Not lately — on a trailing-13-week view Privi Speciality Chemicals Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-08-14), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +1,539% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Privi Speciality Chemicals Ltd's share price go up?
This page publishes no price forecast for Privi Speciality Chemicals Ltd. What it measures instead: the share price is ₹3,556, the price is in a confirmed uptrend 73 weeks in. Its P/E of 39.7× sits at the 48th percentile of its own 9-year range. — as of 11 September 2026.
Who owns Privi Speciality Chemicals Ltd?
Promoters hold 60.6% of Privi Speciality Chemicals Ltd, foreign institutions 1.9%, domestic institutions 10.1% and the public 27.4% (latest quarter). The biggest move on the register over the last two years: Promoters cut 13.4 points over 8 quarters. — as of 11 September 2026.
Does Privi Speciality Chemicals Ltd have too much debt?
It is moderate — Privi Speciality Chemicals Ltd's debt-to-equity is 0.72, and operating profit covers the interest bill 8×. FY26 borrowings were ₹1,021 Cr against equity of ₹1,412 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Privi Speciality Chemicals Ltd's capex?
Privi Speciality Chemicals Ltd spent ₹765 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹330 Cr, with ₹314 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Privi Speciality Chemicals Ltd's cash flow?
Privi Speciality Chemicals Ltd generated ₹550 Cr of operating cash flow in FY26 and ₹220 Cr of free cash flow after ₹330 Cr of capital spending. Reported profit that year was ₹317 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Privi Speciality Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 198% of Privi Speciality Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹550 Cr against reported profit of ₹317 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Privi Speciality Chemicals Ltd in its business cycle?
Privi Speciality Chemicals Ltd's FY26 operating margin was 25.0%, against a 10-year band of 12.0%–25.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 23.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Privi Speciality Chemicals Ltd's price assume?
At its price on 26 August 2026, Privi Speciality Chemicals Ltd was priced for profit growth of about 21.9% a year. Profit itself has compounded 31.5% a year over the past 9 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Privi Speciality Chemicals Ltd story?
The sharpest disagreement: Promoters moved −13.4 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Privi Speciality Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Privi Speciality Chemicals Ltd's earnings have outrun its stock. EPS grew +75.1% in a year against a +52.1% price move. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!